South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Celltrion plans to buy back 100 billion won ($69 million) in stocks, purchasing 554,632 shares starting Thursday.

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...

Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...

Celltrion announced on Friday that it has received construction approval to build a new drug product (DP) manufacturing plant in Songdo, Incheon. The new facility, permitted by the Incheon Free ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT ...